In his 2001 book, A Question of Intent, former Food and Drug Administration (FDA) Commissioner David Kessler highlighted research long suppressed by Big Tobacco that showed how reduced-nicotine ...
The End-of-Phase 2 meeting resulted in alignment with the FDA on the proposed Phase 3 study design, including the inclusion/exclusion criteria, primary and secondary efficacy objectives, definition of ...
Results that may be inaccessible to you are currently showing.